IP Library Granted Patent US 8,153,119
Granted Patent B2
US 8,153,119 · App. 12/337,677 · Granted Apr 10, 2012

Engineered enzymatically active bacteriophage and methods for dispersing biofilms

Assignees: Trustees of Boston University; Massachusetts Institute of Technology
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,119
App. No.
12/337,677
Granted
Apr 10, 2012
Kind
B2
Abstract

The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in Staphylococcus and E. coli , including E. coli K-12, as well as clinical isolates.

Claims (10)

1. A method of dispersing a bacterial biofilm on a surface comprising administering to said surface a genetically engineered lytic T7 bacteriophage wherein the bacteriophage comprises a nucleic acid encoding dispersin B enzyme operably linked to a strong promoter and a nucleic acid encoding a protein to enhance or expand infectivity and or replication capacity of the lytic T7 bacteriophage, wherein the nucleic acid encoding the protein to enhance or expand infectivity and or replication capacity of the lytic T7 bacteriophage encodes T3 1.2 protein.

2. The method of claim 1 , wherein the strong promoter is T7 φ10.

3. The method of claim 1 , wherein the biofilm is a mature biofilm.

4. The method of claim 1 , wherein the biofilm comprises β-1,6-N-acetyl-D-glucosamine.

5. The method of claim 4 further comprising a step of prior to administering the bacteriophage, determining if the biofilm comprises β-1,6-N-acetyl-D-glucosamine, and if it does, then administering the engineered lytic bacteriophage.

6. The method of claim 1 , wherein the biofilm is formed by— Staphylococcus and E. coli , including E. coli K-12 strain, and clinical isolates of E. coli.

7. The method of claim 1 , wherein the administering is performed once.

8. The method of claim 1 , wherein the administering is performed before, after or concurrently with an antibiotic or antimicrobial agent.

9. The method of claim 1 , wherein the administering is performed before, after or concurrently with a biofilm degrading chemical.

10. The method of claim 1 , wherein the phage further comprises a terminator sequence.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 20, 2010
From: BOSTON UNIVERSITY CHARLES RIVER CAMPUS
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 024414/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2009
From: COLLINS, JAMES J.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 022317/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2009
From: LU, TIMOTHY KUAN-TA
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 022306/0169 →
Continuity (2)
Provisional Application 61014518 · Dec 18, 2007
Related Publication 20090155215A1 · Jun 18, 2009